Acute cardiac overload does not induce cardiac or skeletal expression of fibroblast growth factor 23 in rats
Abul Fajoia,b, Hirotaka Komaba,a,b,c, Chigusa Ishiokaa,b, Takehiko Wadaa and Masafumi Fukagawa a

Objective Elevated fibroblast growth factor 23 (FGF23) is associated with cardiovascular events, particularly heart failure. Although FGF23 has been reported to induce cardiac hypertrophy, recent studies demonstrated that cardiac hypertrophy and myocardial infarction induce FGF23 production by cardiomyocytes. We aimed to explore whether acute cardiac overload increases cardiac and skeletal FGF23 expression and circulating FGF23 levels.

Methods We administered 30 µL/g bodyweight of isotonic saline intraperitoneally in rats to induce acute cardiac overload. We measured serum FGF23 levels and other parameters of mineral metabolism at 2, 6, and 24 h after saline or sham injection. We also analyzed gene expression in the heart, calvarium, femur, and kidney at 2 and 24 h after injection.

Results Acute saline injection induced cardiac overload as evidenced by a significant upregulation of brain natriuretic peptide along with a trend towards increased expression of atrial natriuretic peptide and mild hyponatremia. However, there were no changes in serum FGF23 levels or FGF23 expression in the heart, calvarium, or femur.

Conclusions Acute cardiac overload by saline injection in rats did neither induce FGF23 expression in the heart or bone nor did it increase serum FGF23 levels. These findings suggest that more severe or long-term cardiac damage is required for induction of FGF23 expression.

Introduction Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that plays a major role in the regulation of phosphate and vitamin D metabolism. FGF23 primarily acts on the kidneys to induce urinary phosphate excretion by downregulating the sodium-dependent phosphate cotransporters Napi2a and Napi2c and suppress 1,25-dihydroxyvitamin D 1,25(OH)2D synthesis by altering the vitamin D-metabolizing enzymes CYP27b1 and CYP24a1 [1–3]. These functions of FGF23 are mediated by binding to FGF receptor 1 (FGFR1) and the transmembrane protein Klotho, which forms a specific receptor complex for FGF23 [4,5].

Importantly, recent observational studies have shown strong associations between elevated FGF23 and greater risk of cardiovascular events, particularly congestive heart failure, in patients with chronic kidney disease [6–8], hemodialysis patients [9,10], and individuals with apparently normal kidney function [11–15]. Furthermore, elevated FGF23 has been linked to volume overload, a common manifestation of heart failure [16–18].

As a potential mechanism of these observations, FGF23 is reported to induce cardiac hypertrophy via Klotho-independent signaling through the FGFR4 [19,20]. In addition, FGF23 increases renal sodium reabsorption by upregulating the Na+/Cl− cotransporter in the distal tubules via a Klotho-dependent pathway, leading to volume expansion, hypertension, and cardiac hypertrophy [21]. Interestingly, recent studies demonstrated an opposite directional relationship—injured cardiomyocyte could produce substantial amounts of FGF23 after myocardial infarction [22] or during cardiac hypertrophy [23]. However, it remains to be determined whether acute volume expansion, which induces hemodynamic congestion and cardiac overload, stimulates FGF23 production by cardiomyocytes.

Here, we report our investigations into the impact of volume expansion by acute saline injection on cardiac and skeletal expressions of FGF23 as well as circulating FGF23 levels in rats.

Materials and methods

Animals Five-week-old male Sprague–Dawley rats were purchased from CLEA Japan (Tokyo, Japan). The rats were housed under standard environmental conditions (23 ± 2°C, 55 ± 10% humidity, 12:12 h light-dark cycle).
and had free access to water and standard rodent chow. At the age of 6 weeks, 30 μL/g bodyweight of isotonic saline was administered intraperitoneally to induce volume overload. Control rats received a sham injection (needle insertion only). Rats were then placed in metabolic cages for 24-h urine collection and were killed for further examination. A subset of rats was killed 2 h after saline or sham injection. All animal experiments were performed in accordance with institutional guidelines and were approved by the Institutional Animal Care and Use Committee at Tokai University.

**Blood pressure**

We measured blood pressure at 2, 6, and 24 h after saline or sham injection using a computerized tail-cuff system (MK-2000; Muromachi Kikai, Tokyo, Japan). Before recording blood pressure, rats were trained to familiarize themselves with the measurement equipment. Blood pressure values were recorded five times and the results were averaged for each rat.

**Serum and urine biochemistries**

Blood was collected from the tail vein or heart at 2, 6, and 24 h after saline or sham injection. Blood urea nitrogen (BUN), serum creatinine, sodium, calcium, and phosphorus, and urinary sodium levels were measured using standard methods. Serum parathyroid hormone (PTH) levels were measured using a rat intact PTH ELISA (Immutopics, San Clemente, California, USA). Serum FGF23 levels were measured using an intact FGF23 ELISA, which exclusively measures the full-length protein (Kainos Laboratories, Tokyo, Japan). Serum
1,25(OH)\(_2\)D levels were measured using a radioimmunoassay (Immunodiagnostic Systems, Fountain Hills, Arizona, USA).

**Gene expression**

Total RNA was isolated from the femur, calvarium, heart, and kidney using TRIzol reagent (Thermo Fisher Scientific, Waltham, Massachusetts, USA) according to the manufacturer’s instruction. For isolation from femurs, epiphyses were cutoff, bone marrow was removed by centrifugation, and bone tissue was homogenized using a Shake Master NEO (BioMedical Sciences, Tokyo, Japan) together with TRIzol reagent and 5-mm stainless beads. cDNA synthesis was performed using 0.5 µg RNA and SuperScript IV VILO Master Mix with ezDNase Enzyme (Thermo Fisher Scientific). Quantitative real-time PCR was performed on the StepOnePlus System (Thermo Fisher Scientific) using the TaqMan One-Step RT-PCR Master Mix Reagents kit (Thermo Fisher Scientific). Glyceraldehyde-3-phosphate dehydrogenase served as the reference gene to normalize expression.

**Statistical analysis**

Data are represented as mean ± SD. Differences were evaluated using \(t\)-tests or mixed-effects models, as
appropriate. \( P < 0.05 \) was considered statistically significant. All analyses were performed using IBM SPSS Statistics 24 (IBM, Tokyo, Japan).

**Results**

Compared to sham-injected rats, saline-injected rats showed a transient and small decrease in BUN and serum creatinine (Fig. 1a and b), presumably as a result of dilution. The saline-injected rats also showed mild hyponatremia, a hallmark of heart failure, at 24 h after injection (Fig. 1c). These rats had higher systolic blood pressure (Fig. 1d) and diastolic blood pressure (data not shown) at 6 and 24 h, although the difference was not significant. As expected, 24-h urinary sodium excretion was markedly increased in saline-injected rats (Fig. 1e). The increase in urinary sodium excretion was virtually the same as the dose of sodium administered, suggesting recovery from volume expansion at 24 h. Urine volume also tended to increase in saline-injected rats (Fig. 1f), with a difference that was not significant but corresponded to the volume of saline administered.

Next, we investigated the hearts obtained from the saline- and sham-injected rats. While the gross appearance and the ratio of heart weight standardized to total body weight did not differ between saline- and sham-injected rats (Fig. 1g), saline injection led to increased expression of *brain natriuretic peptide* (BNP) and a trend towards increased expression of *atrial natriuretic peptide* (ANP) \((P = 0.07)\) (Fig. 2a), suggesting cardiac stress in response to volume overload. Expression of \( \beta \)-*myosin heavy chain* (\( \beta \)-MHC) was comparable between saline- and sham-injected rats, suggesting that the transient volume expansion after saline injection did not activate hypertrophic gene programs.

To explore whether cardiac overload by saline injection affects FGF23 synthesis by cardiomyocytes or osteoblasts/osteocytes, we examined gene expression in the heart and bone. We found no changes in *FGF23* expression.
expression in the heart, calvarium, or femur after saline injection (Fig. 2b). Recent studies reported weak but significant expression of FGF23 in the kidney [24], but there was no difference in renal expression of FGF23 between saline- and sham-injected rats. It is reported that FGF23 induces cardiac hypertrophy by Klotho-independent binding to FGFR4 [20]. However, the expression of FGFR4 in the heart was much lower than that in the kidney, and these expressions did not change by saline injection (Fig. 2c). As expected, the expression of Klotho was abundant in the kidney but was almost undetectable in the heart. Overall, there was no significant difference in serum FGF23 levels between saline- and sham-injected rats (Fig. 3a), although serum FGF23 levels tended to decrease at 6 h after saline injection ($P = 0.07$). There was a transient decrease in serum intact PTH levels at 2 h after saline injection (Fig. 3b), which is the same time point when BUN and serum creatinine decreased (Fig. 1a and b). Serum calcium, phosphorus, and $1,25(OH)_{2}D$ levels were comparable between saline- and sham-injected rats (Fig. 3c–e). We also measured the renal expression of genes involved in mineral metabolism, but there was no significant difference in expression of Napi2a, Cyp27b1, or Cyp24a1 between saline- and sham-injected rats (data not shown).

**Discussion**

Elevated FGF23 has emerged as having a strong association with cardiovascular events, cardiac hypertrophy, congestive heart failure, and volume overload [6–18]. Recent investigations demonstrated that cardiomyocytes are the source of FGF23 in animal models of myocardial infarction [22] and cardiac hypertrophy induced by transverse aortic constriction or cardiomyocyte-specific activation of calcineurin A [23]. Based on these reports, we hypothesized that acute cardiac volume overload stimulates FGF23 production by cardiomyocytes. To address this, we injected isotonic saline in rats, which produced a significant upregulation of BNP along with a trend towards increased expression of ANP and mild hyponatremia. However, there were no changes in serum FGF23 levels or FGF23 expression in the heart, calvarium, or femur.

Our findings contrast with previous observations of increased serum FGF23 levels and increased cardiac expression of FGF23 in rodents with myocardial infarction [22] and cardiac hypertrophy [23]. The major difference between those studies and ours is the etiology and severity of heart disease. While we were able to induce a significant upregulation of cardiac BNP by saline injection, the compensatory increase in urinary sodium excretion appeared to limit the volume expansion and thereby the pathological impact on cardiomyocytes, as suggested by the lack of changes in cardiac $MHC$. Thus, our findings that transient volume expansion by saline injection did not induce cardiac FGF23 expression along with previous results in models of myocardial infarction [22] and more pronounced cardiac hypertrophy [23] suggest that induction of cardiac FGF23 expression requires pathological processes in the heart such as hypertrophy and fibrosis. This possibility is further supported by recent human studies showing that circulating FGF23 levels were associated with the severity of heart failure [18], but these levels did not change after acute injection of isotonic saline in patients with arterial hypertension [25]. Future research should determine whether chronic volume expansion stimulates cardiac FGF23 expression and whether this process requires hypertrophic growth of cardiomyocytes.

The synthesis of FGF23 by osteoblasts/osteocytes is mainly regulated by phosphate [26], calcium [27], $1,25(OH)_{2}D$ [28], and PTH [29], but recent investigations revealed that aldosterone is also involved in this regulation [30]. Aldosterone acts on osteoblasts through the mineralocorticoid receptor to stimulate FGF23 production. It is unknown whether aldosterone also stimulates FGF23 synthesis in cardiomyocytes; but if so, there is a possibility that decreased aldosterone in response to volume expansion might have offset the effects of cardiac overload on cardiomyocyte expression of FGF23. Additional studies are required to address this possibility.

In the present study, we observed consistent reductions in BUN, serum creatinine, and intact PTH levels at 2 h after intraperitoneal saline injection, which could be explained by a dilution effect. However, no such reduction was observed for serum FGF23 levels at this time point, raising the possibility that volume expansion might have rapidly increased FGF23 secretion by bone cells in which a large amount of FGF23 is stored. However, this possibility is unlikely because serum FGF23 levels tended to decrease at 6 h after saline injection. Furthermore, the expression of FGF23 in the bone did not change at 2 or 24 h after saline injection. Thus, we conclude that volume expansion by saline injection does not induce FGF23 production by bone cells.

Interestingly, our findings that cardiac overload did not enhance skeletal expression of FGF23 are consistent with the study of cardiac hypertrophy [22], but not with another study showing that myocardial infarction induced FGF23 expression in the bone as well as the heart [23]. These apparently conflicting results could be reconciled if we assume that injured cardiomyocytes after myocardial infarction release a factor that enhances FGF23 expression in bone cells. Of note, a recent study has demonstrated that during acute kidney injury, kidney-derived glycerol-3-phosphate, a downstream product of glycolysis, acts on bone cells to stimulate FGF23 production [31]. Future research should determine whether glycerol-3-phosphate or other factors derived from injured cardiomyocytes are involved in the enhanced FGF23 expression in bone cells after myocardial infarction.
Conclusion
We demonstrated that acute cardiac overload by saline injection in rats did neither induce FGF23 expression in the heart or bone nor did it increase serum FGF23 levels. These findings, together with previous results in models of myocardial infarction and cardiac hypertrophy, suggest that more severe or long-term cardiac damage is required for induction of FGF23 expression. Additional studies are required to determine this possibility.

Acknowledgements
A.F. is a JSPS International Research Fellow. We thank Ms. Sachie Tanaka and Mr. Shuho Hori, the Support Center for Medical Research and Education, Tokai University.

Conflicts of interest
H.K. has received honoraria, consulting fees, or grant support from Bayer Yakuhin, Chugai Pharmaceutical, Japan Tobacco, Kyowa Kirin, Novartis, and Ono Pharmaceutical. T.W. has received honoraria, consulting fees, or grant support from Chugai Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, and Otsuka Pharmaceutical. M.F. has received honoraria, consulting fees, or grant support from Astellas Pharma, Bayer Yakuhin, Kissei Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, and Torigi Pharmaceutical. For the remaining authors, there are no conflicts of interest.

References
1 Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98:6500–6505.
2 Shimada T, Kakinari M, Yamaizaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of Fgfr3 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113:561–568.
3 Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenhuses HS, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2001; 145:3087–3094.
4 Urakawa I, Yamaizaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770–774.
5 Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120–6123.
6 Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22:1913–1922.
7 Sicalla JJ, Xie H, Rahman M, Anderson AH, Isaakova T, Ojo A, et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014; 25:349–360.
8 Seiler S, Rogacev KS, Roth HJ, Shafiee P, Emrich I, Neuhaus S, et al. Associations of FGF23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol 2014; 9:1049–1058.
9 Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, et al.; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 2015; 132:27–39.
10 Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infection and cardiac deaths in the HEMO study. J Am Soc Nephrol 2016; 27:227–237.
11 Parker BD, Schurgers LJ, Brandenburg VM, Christensen RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study. Ann Intern Med 2010; 152:640–648.
12 Inoue K, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60:200–207.
13 di Giuseppe R, Buijsse B, Bircher F, Wirth J, Arendt M, Westphal S, et al. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab 2014; 99:947–955.
14 Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the multi-ethnic study of atherosclerosis. Circ Heart Fail 2014; 7:409–417.
15 Lutsey PL, Alonso A, Selvin E, Pankow JS, Michos ED, Agarwal SK, et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study. J Am Heart Assoc 2014; 3:e000936.
16 Baic LG, Humalda JK, Vervloet MG, Navis G, Bakker SJ, de Borst MH; NIGRAM Consortium. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 2013; 8:1968–1978.
17 Humalda JK, Riphagen U, Assa S, Hummel YM, Westerhuis R, Vervloet MG, et al.; NIGRAM Consortium. Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis. Nephrol Dial Transplant 2016; 31:1494–1501.
18 Ter Maaten JM, Voors AA, Damman K, van der Meer P, Anker AD, Cieland JG, et al. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. Int J Cardiovasc 2018; 253:84–90.
19 Faul C, Anarai AP, Osikouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393–4408.
20 Grajber A, Anarai AP, Scharmm J, Singh S, Sloan A, Yanuci C, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 2015; 22:1020–1032.
21 Andrukhova O, Slavic S, Smrodzenkko A, Zeitz U, Shallhoub V, Lanske B, et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med 2014; 6:744–759.
22 Andrukhova O, Slavic S, Odörfer KI, Erben RG. Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. J Bone Miner Res 2015; 30:1831–1839.
23 Matsui I, Oka T, Kusunoki Y, Mori D, Hashimoto N, Matsumoto A, et al. Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23. Kidney Int 2010; 78:60–71.
24 Smith ER, Tan SJ, Holt SG, Hewitson TD. FGF23 is synthesised locally by renal tubules and activates injury-induced fibroblasts. Sci Rep 2017; 7:3345.
25 Humalda JK, Seiler-Muler S, Kwackmaer AJ, Vervloet MG, Navis G, Fiser D, et al. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine (Baltimore) 2016; 95:e5003.
26 Takashi Y, Kosako H, Sawatsubashi S, Kinoshita Y, Ito N, Tsoumpra MK, et al. Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation. Proc Natl Acad Sci USA 2019; 116:11418–11427.
27 David V, Dai B, Martin A, Huang J, Han X, Quarles LD. Calcium regulates FGF23 expression in bone. Endocrinology 2013; 154:4469–4482.
28 Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, et al. Circulating FGF23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280:25434–25439.
29 Lavi-Moshayv V, Wasserman G, Meer T, Silver J, Navheh-May T, PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299:F882–F889.
30 Zhang B, Umbach AT, Chen Y, Yan J, Fakhri H, Fajol A, et al.; Up-regulation of FGF23 release by aldosterone. Biochem Biophys Res Commun 2016; 470:384–390.
31 Simic P, Kim W, Zhou W, Pierce KA, Chang W, Sykes DB, et al. Glyceraldehyde-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest 2020; 130:1513–1526.